Fig. 6
Blocking IL-1R relieves disease symptoms. iOvaFla; LysM-Cre+/− mice with significant joint swelling at 4.0 mm were administered either anti-IL-1R blocking antibody or isotype control every 3–4 days for 2 weeks. a Their weights and tibiotarsal joints were measured during that time (n = 7 biological replicates per treatment). b Post-treatment serum cytokines measured by a BD Biosciences cytokine bead array and IL-18 ELISA. c Flow cytometry and d quantification of monocytes (MO; CD11b+ Ly6CHi Ly6GLo) and neutrophils (NE; CD11b+ Ly6CLo Ly6GHi). For each flow cytometry plot, the top row is from the spleen and the second row from peripheral and mesenteric lymph nodes. Each column represents a different treatment. Data in b–d are representative of three independent experiments. Error bars are s.d. Results were analysed with either a Mann–Whitney test or two-way ANOVA and Bonferroni post-tests; *p < 0.05, **p < 0.01, ***p < 0.001
